Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 5/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 5/20 | 0.40 |
| ▸ | ITGAL | P20701 | 5/20 | 0.40 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.36 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944583 | 1.00 | ITGB2 (0.40) | ITGB2ICAM1ITGALGPER1HRH1 | |
| SCHEMBL3944588 | 1.00 | ITGB2 (0.40) | ITGB2ICAM1ITGALGPER1HRH1 | |
| SCHEMBL3946995 | 0.90 | EPHX2 (0.44) | GPER1EPHX2TEAD1 | |
| SCHEMBL3946999 | 0.90 | EPHX2 (0.44) | GPER1EPHX2TEAD1 | |
| SCHEMBL3946996 | 0.90 | EPHX2 (0.44) | GPER1EPHX2TEAD1 | |
| SCHEMBL3938107 | 0.86 | SLC2A1 (0.41) | ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL3938104 | 0.86 | SLC2A1 (0.41) | ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL3938099 | 0.86 | SLC2A1 (0.41) | ITGB2ICAM1ITGALEPHX2 | |
| SCHEMBL3948188 | 0.82 | EPHX2 (0.51) | EPHX2TEAD1 | |
| SCHEMBL3948185 | 0.82 | EPHX2 (0.51) | EPHX2TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | ITGB2 3540/4885ICAM1 4862/4885ITGAL 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.